

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	G Medical Innovations Holdings Limited
ARBN	617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yacov Geva
Date of last notice	17 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<div><div>1</div>Indirect</div> <div><div>2</div>Indirect</div> <div><div>3</div>Indirect</div> <div><div>4</div>Direct</div>
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<div><div>1</div>Beneficial holding held through and registered in the name of Bank Julius Baer & Co Ltd</div> <div><div>2</div>Beneficial holding held through custodian and registered in the name of HSBC Custody Nominees (Australia) Limited</div> <div><div>3</div>Beneficial holding held through custodian and registered in the name of J P Morgan Nominees Australia Pty Limited</div> <div><div>4</div>Direct</div>
Date of change	21 May 2019 and 23 May 2019
No. of securities held prior to change	<div><div>1</div>Indirect<div><div>a.</div>193,036,154 fully paid ordinary shares</div><div><div>b.</div>49,745,275 Class C Performance Rights</div></div> <div><div>2</div>Indirect – 3,672,000 fully paid ordinary shares</div> <div><div>3</div>Indirect - Nil</div> <div><div>4</div>Direct - Nil</div>

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Fully paid ordinary shares
Number acquired	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. 193,036,154 4. 14,706,719
Number disposed	<ol style="list-style-type: none"> 1. 193,036,154 2. Nil 3. Nil 4. Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> 1. Nil. Off-market transfer of 193,036,154 shares. 2. Nil. Deemed issue price of US\$0.226 per share.
No. of securities held after change	<ol style="list-style-type: none"> 1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 193,036,354 fully paid ordinary shares 4 14,706,719 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> 1. Off-market transfer of 193,036,154 shares from Bank Julius Baer & Co Ltd to J P Morgan Nominees Australia Pty Limited 2. 14,706,719 shares issued in settlement of US\$3,317,500 of principal and interest in respect of a loan facility, as approved by shareholders at the shareholder meeting held 24 April 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.